Duan C A X, Sui B Y, Chen Z D, Zhao K
China National Health Development Research Center, Beijing 100044, China.
WHO Representative in the People's Republic of China, Beijing 100600, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Oct 6;54(10):1161-1164. doi: 10.3760/cma.j.cn112150-20191009-00769.
The oral direct-acting antiviral drug (DAA) offers tremendous opportunities to eliminate hepatitis C. We analyzed the market trends, price trends and global treatment progress of DAA drugs by reviewing the guidelines recommended by the World Health Organization for the treatment of hepatitis C, and discusses the current accessibility of DAA treatment and its influencing factors. The results show that WHO recommends the use of DAA for treatment of hepatitis C, but the price of DAA is expensive. Although some countries have taken measures to lower prices and improve accessibility, the advancement of DAA treatment has been unsatisfactory and coverage is still not high. In addition to price, factors such as strategy, health system, accessibility and service provision need to be considered, and public health methods should be adopted to promote DAA treatment to achieve the elimination of hepatitis C.
口服直接抗病毒药物（DAA）为消除丙型肝炎提供了巨大机遇。我们通过回顾世界卫生组织推荐的丙型肝炎治疗指南，分析了DAA药物的市场趋势、价格趋势和全球治疗进展，并讨论了目前DAA治疗的可及性及其影响因素。结果表明，世界卫生组织推荐使用DAA治疗丙型肝炎，但DAA价格昂贵。尽管一些国家已采取措施降低价格并提高可及性，但DAA治疗的进展并不理想，覆盖率仍然不高。除价格外，还需要考虑策略、卫生系统、可及性和服务提供等因素，并应采用公共卫生方法来促进DAA治疗以实现丙型肝炎的消除。
